Deals > All

France Monaco Central France Eastern France Northern France Paris (region) Southern France Western France

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in France and Monaco or involving organisations from these countries.

Total search results: 2099 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Deal: Collaboration or Financing	Date
Catalym–Jeito Capital: investment, 202211 financing round Series C totalling €50m incl new + co-lead investor Jeito Capital	2022-11-22
Catalym–SEVERAL: investment, 202211 financing round Series C €50m led by Brandon Capital + Jeito Capital	2022-11-22
Cradle Bio–PERSON: investment, 202211 seed financing round totalling €5.5m incl angel investor Sylvain Gariel	2022-11-17
Sarcura–SEVERAL: investment, 202211 seed plus financing round €7m co-led by Lansdowne Investment Co Cyprus + IST Cube	2022-11-17
BC Platforms–Jolt Capital: investment, 202211 growth financing round totalling CHF20m incl new + lead investor Jolt Capital	2022-11-08
BC Platforms–SEVERAL: investment, 202211 growth financing round CHF20m led by new investor Jolt Capital	2022-11-08
Normunity–SEVERAL: investment, 202210 financing round Series A $65m led by Canaan Ventures + company launch announced	2022-10-25
Aqemia–SEVERAL: investment, 202210 financing round Series A €30m led by Eurazeo + Bpifrance Large Venture Fund	2022-10-19
Univercells–SEVERAL: investment, 202210 financing round Series D 1st closing €44m with SFPI-FPIM + SRIW et al	2022-10-19
MS-Omics–Clinical Microbiomics: investment, 202210 acquisition of MS-Omics ApS by Clinical Microbiomics A/S	2022-10-17
Mablink Bioscience–Crédit Agricole: investment, 202210 financing round Series A totalling €31m incl existing + co-investor Crédit Agricole Création	2022-10-14
Mablink Bioscience–Elaia Partners: investment, 202210 financing round Series A totalling €31m incl existing + co-investor Elaia Partners	2022-10-14
Mablink Bioscience–Fournier-Majoie Foundation: investment, 202210 financing round Series A totalling €31m incl existing + co-investor Fondation FM	2022-10-14
Mablink Bioscience–Mérieux: investment, 202210 financing round Series A totalling €31m incl new + co-lead investor Mérieux Equity Partners	2022-10-14
Mablink Bioscience–Pertinence Invest 2: investment, 202210 financing round Series A totalling €31m incl existing + co-investor Pertinence Invest 2	2022-10-14
Mablink Bioscience–SEVERAL: investment, 202210 financing round Series A €31m led by Sofinnova Partners + Mérieux Equity Partners	2022-10-14
Mablink Bioscience–Sham: investment, 202210 financing round Series A totalling €31m incl existing + co-investor Sham Innovation Santé	2022-10-14
Mablink Bioscience–Simba Santé: investment, 202210 financing round Series A totalling €31m incl existing + co-investor Simba Santé	2022-10-14
Mablink Bioscience–Sofinnova: investment, 202210 financing round Series A totalling €31m incl new + co-lead investor Sofinnova Partners	2022-10-14
Clinical Microbiomics–BPCE: investment, 202210 investment €10m from Health for Life Capital II fund managed by Seventure Partners	2022-10-11
Andera Partners–SEVERAL: investment, 202210 final closing of BioDiscovery 6 fund at €456m	2022-10-10
Cevec–Danaher: investment, 202210 acquisition of Cevec by Cytiva	2022-10-06
Matchpoint Therapeutics–Sanofi: investment, 202210c financing round Series A totalling $70m incl new + lead investor Sanofi Ventures	2022-10-01
Valneva–SEVERAL: investment, 202209–202210 private placement €100-45m of 20.5m ordinary shares at €4.9/share	2022-09-28
Valneva–SEVERAL: investment, 202209–202210 public offering $3.57m of 375k ADSs (each = 2 ordinary shares) at $9.51/ADS	2022-09-28
EFOS (SI)–Demeter: investment, 202209 financing round Series B totalling €10m incl co-investor VitiRey Innovation fund	2022-09-20
EFOS (SI)–Pymwymic: investment, 202209 financing round Series B totalling €10m incl existing + co-investor Pymwymic	2022-09-20
EFOS (SI)–SEVERAL: investment, 202209 financing round Series B €10m led by ECBF	2022-09-20
Flash Therapeutics–Techlife Capital: investment, 202209 existent investment of Techlife Capital	2022-09-20
Mitem Pharma–Techlife Capital: investment, 202209 existent investment of Techlife Capital	2022-09-20
MyData Trust–Techlife Capital: investment, 202209 existent investment of Techlife Capital	2022-09-20
Quinten–MACSF: investment, 202209 financing round totalling €14m incl investor MACSF	2022-09-20
Quinten–SEVERAL: investment, 202209 financing round €14m growth equity investment for Quinten Health from Techlife Capital + MACSF	2022-09-20
Quinten–Techlife Capital: investment, 202209 financing round totalling €14m incl investor Techlife Capital	2022-09-20
XPath–Techlife Capital: investment, 202209 existent investment of Techlife Capital	2022-09-20
Versantis–Genfit: investment, 202209– acquisition CHF40m upfront + CHF65m milestones + 1/3 of net proceeds of eventual PRV	2022-09-19
SparingVision–SEVERAL: investment, 202209 financing round Series B €75m led by Jeito Capital + UPMC Enterprises	2022-09-15
Tridek-One–AdBio Partners: investment, 202209 2nd financing round totalling €16m incl existing + co-investor AdBio Partners	2022-09-15
Tridek-One–Advent Life Sciences: investment, 202209 2nd financing round totalling €16m incl existing + co-investor Advent Life Sciences	2022-09-15
Tridek-One–Bellevue: investment, 202209 2nd financing round totalling €16m incl new + lead investor Pureos Bioventures	2022-09-15
Tridek-One–Bioqube Ventures: investment, 202209 2nd financing round totalling €16m incl new + co-investor Bioqube Ventures	2022-09-15
Tridek-One–France (govt): investment, 202209 2nd financing round totalling €16m incl new + co-investor Bpifrance via InnoBio 2 Fund	2022-09-15
Tridek-One–SEVERAL: investment, 202209 2nd financing round €16m led by Pureos Bioventures	2022-09-15
Standing Ovation–Astanor Ventures: investment, 202209 financing round Series A totalling €12m incl lead investor Astanor Ventures	2022-09-14
Standing Ovation–SEVERAL: investment, 202209 financing round Series A €12m lead by Astanor Ventures	2022-09-14
Aido–NLC Ventures: investment, 202209 existent seed investor NLC	2022-09-08
Abivax–Column Group: investment, 202209 reserved equity capital increase totalling €46.2m incl new + lead investor TCG X	2022-09-02
Abivax–Deep Track Capital: investment, 202209 reserved equity capital increase totalling €46.2m incl new + co-investor Deep Track Capital	2022-09-02
Abivax–Invus Group: investment, 202209 reserved equity capital increase totalling €46.2m incl co-investor Invus	2022-09-02
Abivax–Rockefeller: investment, 202209 reserved equity capital increase totalling €46.2m incl new + co-investor Venrock Healthcare Capital Partners	2022-09-02
Abivax–Santé Holding: investment, 202209 reserved equity capital increase totalling €46.2m incl €0.8m from existing + co-investor Santé Holding	2022-09-02
Abivax–SEVERAL: investment, 202209 issuance of royalty certificates for €2.9m	2022-09-02
Abivax–SEVERAL: investment, 202209 reserved equity capital increase €46.2m with 5.53m new shares at €8.36/share led by TCG X	2022-09-02
Abivax–Sofinnova: investment, 202209 reserved equity capital increase totalling €46.2m incl €4.9m from existing + co-investor Sofinnova Partners	2022-09-02
Abivax–Truffle Capital: investment, 202209 reserved equity capital increase totalling €46.2m incl €1.6m from existing + co-investor Truffle Capital	2022-09-02
Genome Diagnostics–Eurobio Scientific: investment, 202208– acquisition 100% of GenDx for €135m in cash (net of adjusted cash)	2022-08-17
Albumedix–Sartorius: investment, 202208– acquisition £415m 100% of Albumedix by Sartorius Stedim Biotech ANNOUNCED	2022-08-08
F2G Ltd–Novo Group: investment, 202208 financing round totalling $70m inc existing + co-investor Novo Holdings	2022-08-04
F2G Ltd–SEVERAL: investment, 202208 financing round $70m co-led by new investors Forbion + Sofinnova Partners	2022-08-04
F2G Ltd–Sofinnova: investment, 202208 financing round totalling $70m inc new + co-lead investor Sofinnova Partners	2022-08-04
Forty51 Ventures–Fischli Group: investment, 202207 first closing totalling $43m of Forty51 Ventures I fund incl co-lead investor Fischli Family	2022-07-18
Forty51 Ventures–OTHER: investment, 202207 first closing totalling $43m of Forty51 Ventures I fund incl biotech entrepreneures + private individuals	2022-07-18
Forty51 Ventures–SEVERAL: investment, 202207 first $43m closing of Forty51 Ventures I fund	2022-07-18
Forty51 Ventures–Stable Asset Management: investment, 202207 first closing totalling $43m of Forty51 Ventures I fund incl co-lead investor SAM	2022-07-18
Agomab Therapeutics–OTHER: investment, 202207 financing round Series B extension totalling $40.5m incl existing-investors	2022-07-13
Agomab Therapeutics–SEVERAL: investment, 202207 financing round Series B extension $40.5m led by Pfizer bringing total Series B to $114m	2022-07-13
Biosyntia–ECBF: investment, 202207 financing round Series B totalling €11.5m incl new + lead investor ECBF	2022-07-07
Biosyntia–Novo Group: investment, 202207 financing round Series B totalling €11.5m incl existing + co-investor Novo Seeds	2022-07-07
Biosyntia–SEVERAL: investment, 202207 financing round Series B €11.5m led by new investor ECBF	2022-07-07
Biosyntia–Sofinnova: investment, 202207 financing round Series B totalling €11.5m incl existing + co-investor Sofinnova Partners	2022-07-07
Ganymed Robotics–BNP Paribas: investment, 202207 financing round Series B first closing totalling €21m incl co-investor BNP Paribas Développement	2022-07-07
Ganymed Robotics–Cathay Capital: investment, 202207 financing round Series B first closing totalling €21m incl lead investor Cathay Health	2022-07-07
Ganymed Robotics–Crédit Mutuel-CIC: investment, 202207 financing round Series B first closing totalling €21m incl co-investor Crédit Mutuel Innovation	2022-07-07
Ganymed Robotics–Eurazeo: investment, 202207 financing round Series B first closing totalling €21m incl co-investor Kurma Partners	2022-07-07
Ganymed Robotics–OTHER: investment, 202207 financing round Series B first closing totalling €21m incl internationallly renowned surgeons	2022-07-07
Ganymed Robotics–SEVERAL: investment, 202207 financing round Series B first closing €21m led by Cathay Health	2022-07-07
Aurobac Therapeutics–Boehringer: investment, 202207 launch of €40m joint venture Aurobac incl €30m from lead investor Boehringer Ingelheim	2022-07-06
Boehringer–Evotec: investment, 202207 launch of €40m joint venture Aurobac incl €5m from co-investor Evotec	2022-07-06
Boehringer–Mérieux: investment, 202207 launch of €40m joint venture Aurobac incl €5m from co-investor bioMérieux	2022-07-06
Epizyme–Ipsen: investment, 202206– cash tender offer $247m + 1CVR/share ANNOUNCED	2022-06-27
Micropep Technologies–CEA Industrie: investment, 202206 financing round Series A1 totalling €8.75m incl existing + co-investor Supernova Invest	2022-06-27
Micropep Technologies–Fall Line Capital: investment, 202206 financing round Series A1 totalling €8.75m incl new + lead investor Fall Line Capital	2022-06-27
Micropep Technologies–FMC: investment, 202206 financing round Series A1 totalling €8.75m incl existing + co-investor FMC Ventures	2022-06-27
Micropep Technologies–Irdi Soridec: investment, 202206 financing round Series A1 totalling €8.75m incl existing + co-investor Irdi/Soridec	2022-06-27
Micropep Technologies–SEVERAL: investment, 202206 financing round Series A1 €8.75m led by new investor Fall Line Capital	2022-06-27
Micropep Technologies–Sofinnova: investment, 202206 financing round Series A1 totalling €8.75m incl existing + co-investor Sofinnova Partners	2022-06-27
Kranus Health–Karista: investment, 202206 financing round Series A totalling >$6.5m incl lead investor Karista	2022-06-20
Kranus Health–SEVERAL: investment, 202206 financing round Series A >$6.5m led by Karista	2022-06-20
Valneva–Pfizer: investment, 202206 equity investment via capital increase €90.5m (representing 8.1% if capital) at €9.49/share	2022-06-20
ImCheck Therapeutics–Agent Capital: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Agent Capital	2022-06-13
ImCheck Therapeutics–Alexandria Real Estate: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Alexandria VI	2022-06-13
ImCheck Therapeutics–Andera Partners: investment, 202206 financing round Series C totalling €80m incl new + co-lead investor Andera Partners	2022-06-13
ImCheck Therapeutics–Bellevue: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Pureos Bioventures	2022-06-13
ImCheck Therapeutics–Boehringer: investment, 202206 financing round Series C totalling €80m incl existing + co-investor BIVF	2022-06-13
ImCheck Therapeutics–Earlybird: investment, 202206 financing round Series C totalling €80m incl new + co-lead investor Earlybird	2022-06-13
ImCheck Therapeutics–EQT: investment, 202206 financing round Series C totalling €80m incl existing + co-investor EQT Life Sciences	2022-06-13
ImCheck Therapeutics–Eurazeo: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Eurazeo	2022-06-13
ImCheck Therapeutics–Eurazeo: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Kurma Partners GO Fund	2022-06-13
ImCheck Therapeutics–France (govt): investment, 202206 financing round Series C totalling €80m incl existing + co-investor Bpifrance Innobio 2 + LV	2022-06-13
ImCheck Therapeutics–Gimv: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Gimv	2022-06-13

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Picture University of Siena imss2023 Cagliari Sardinia Italy 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)